Novartis adds PI3Kα asset
Novartis agreed to acquire a pan‑mutant‑selective PI3Kα inhibitor, strengthening its HR+/HER2– breast cancer pipeline and signaling continued demand for molecular stratification of tumors. That trend increases reliance on cytology cell‑blocks and liquid biopsies to provide mutation data in metastatic or unresectable cases. (globenewswire.com)
SNV4818 is the named oral pan‑mutant‑selective PI3Kα inhibitor in the program and is engineered to target mutated PI3Kα while sparing wild‑type PI3Kα to improve tolerability. (novartis.com) Synnovation’s announcement shows the transaction will transfer Pikavation Therapeutics (a Synnovation subsidiary) to Novartis for $2.0 billion upfront plus up to $1.0 billion in development, regulatory and commercial milestones, for total potential cash consideration of up to $3.0 billion. (synnovationtx.com) The lead clinical program is listed on ClinicalTrials.gov as a Phase 1/2, open‑label dose‑escalation and expansion study (NCT06736704 / SNV4818‑101) that began Feb 20, 2025, estimates enrollment of 320 participants and gives a primary completion estimate of April 2027. (clinicaltrials.gov) The study includes monotherapy and combination arms with fulvestrant and palbociclib and specifies inclusion of advanced or metastatic solid tumors with an activating PIK3CA mutation, with eligibility permitting disease evaluable by clinically relevant tumor biomarkers in blood. (ctv.veeva.com) Novartis and Synnovation materials quantify the target population, stating approximately 40% of HR+/HER2‑ breast cancer patients harbor PIK3CA mutations that drive the program’s biomarker‑dependent design. (novartis.com) The trial record lists 12 sites across the U.S. and Australia, including The Angeles Clinic (Cedars‑affiliated), Massachusetts General Hospital, Thomas Jefferson University‑Sidney Kimmel Cancer Center and MD Anderson Cancer Center, establishing concrete regional demand points for validated PIK3CA testing workflows. (clinicaltrials.gov) The transaction is reported as expected to finalize in the first half of 2026 while the SNV4818 trial’s primary completion is estimated April 2027, anchoring a regulatory and clinical timeline that will drive PIK3CA mutation testing activity at participating centers through 2026–2027. (synnovationtx.com)
